Videos

AI-enabled ECG may help detect liver disease earlier, offering a new path to close diagnostic gaps and shift toward preventive hepatology in clinical practice.

Su described how NNAALs drive management decisions in pregnancy and post partum care.

Accelerated 5×5 rTMS delivers comparable outcomes to standard protocols, offering faster treatment with key tradeoffs in cost, access, and response timing.

Neuen reflects on new FIND-CKD data suggesting finerenone’s benefit in nondiabetic chronic kidney disease and highlights urgency of early screening and combination therapy.

Data from 39 kidney biopsies may challenge longterm beliefs about diabetic nephropathy in CKD.

In a rapidly evolving therapeutic landscape, how can clinicians make decisions to personalize IgAN care?

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting the shifting attitude towards hypertriglyceridemia treatment.

This discussion reflects on great speakers, the unique pressures women face on the podium, and what it takes to build a national platform in academic medicine.

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting the return of LDL-C target goals for ASCVD prevention.

Allocating lower but acceptable quality kidneys to high-risk patients could introduce equity.

This segment of the latest episode of The Medical Sisterhood highlights insights into the career of Natasha Mesinkovska, MD, PhD.

At AAAAI 2026, Ramsey discussed the shift toward race-neutral spirometry equations, their clinical implications, and barriers to widespread adoption.

Even Routine Urinalysis Can Reveal Hidden IgA Nephropathy, Especially in Young Adults

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting PREVENT and a renewed focus on Lp(a).

McDonald discusses new trial data suggesting an initial vancomycin taper may reduce early recurrence of C difficile infection.

This segment of Eichenfield's interview highlights long-term safety findings on roflumilast cream .05% for children 2 - 5 years old with atopic dermatitis.

This conference preview with Kathryn Berlacher, MD, MS, and Kristen Campbell, PharmD, highlights the top 6 trials to watch at ACC 2026.

This interview highlights key points regarding new data on roflumilast cream 0.05% in children aged 2 to 5 years with atopic dermatitis.

Nicole Negbenebor, MD, discusses how writing and collaboration help advance dermatologic research and patient advocacy.

At AAAAI 2026, Anna Nowak-Wegrzyn, MD, discussed the use of ondansetron, home management strategies, and guidance on the gradual reintroduction of foods in FPIES.

Research presented at AAAAI 2026 found that 88% of participants preferred intranasal epinephrine over injectables.

With new therapies emerging for hepatitis D, Kushner discusses brelovitug’s potential and what will be learned from the phase 3 AZURE program.

Lala discusses ongoing challenges in the HF treatment cascade, highlighting widespread misunderstandings among patients and the issue of extreme pill burden.

This March episode of The Medical Sisterhood, in honor of Women's History Month, covers building influence in the dermatology field as a woman physician.

Bialo discusses her perspective on the importance of T1D screening and its capacity to reduce the risk of disease progression and eventual complications later in life.

Data presented at AAAAI 2026 showed that adding dupilumab to omalizumab-facilitated oral immunotherapy improved desensitization and reduced gastrointestinal adverse events.

7 experts come together to address neighborhood disadvantage and its impact on kidney health in the latest Crisis Point.

Wood discussed the potential of BTK inhibition for peanut allergy and beyond.